This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ProPhase Labs, Inc. (PRPH) Soars 7.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 3.51% and 16.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for ProPhase Labs (PRPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ProPhase Labs (PRPH) stock based on the movements in the options market lately.
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing Assertio (ASRT) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog highlights Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs
by Zacks Equity Research
Consolidated Water, Ashford Hospitality Trust, BankFinancial, LogicBio Therapeutics and ProPhase Labs are part of the Zacks top Analyst Blog .
5 Big Winners as Dollar Strengthens on Fed Rate Hike
by Tirthankar Chakraborty
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?
by Zacks Equity Research
Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.
5 Cheap Healthcare Stocks in 2022
by Tracey Ryniec
Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?
Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) closed at $10.47 in the latest trading session, marking a -1.87% move from the prior day.
Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks.com featured highlights include USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse
by Zacks Equity Research
USA Truck, Franklin Covey, ProPhase Labs, Daqo New Energy and The Chefs' Warehouse are part of zacks screen of the week article.
5 Stocks With Recent Price Strength for a Steady Portfolio
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are USAK, FC, PRPH, DQ and CHEF.
ProPhase Labs, Inc. (PRPH) Soars 9.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
ProPhase Labs, Inc. (PRPH) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ProPhase Labs, Inc. (PRPH) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ProPhase Labs, Inc. (PRPH) and RVL Pharmaceuticals PLC (RVLP) have performed compared to their sector so far this year.
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program
by Zacks Equity Research
Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.